Cilengitide is a cyclic peptide integrin antagonist investigated for its potential to inhibit angiogenesis by blocking the binding of VEGF and PDGF to cell surface receptors. This research compound has… Read more
Cilengitide is a cyclic peptide integrin antagonist investigated for its potential to inhibit angiogenesis by blocking the binding of VEGF and PDGF to cell surface receptors. This research compound has been studied in clinical trials for treating various malignancies, including glioblastoma, sarcoma, and lung cancer. In pharmaceutical development and analytical research, high-quality reference standards are essential for characterizing this peptide and its associated degradation products. The selection includes Cilengitide API, along with its pharmacopeial and non-pharmacopeial impurities, potential metabolites, and stable isotope-labelled compounds. These materials are critical for researchers conducting impurity profiling, method validation, and rigorous quality control in bioanalytical assays. By utilizing these precise reference materials, laboratories can ensure the accuracy and reproducibility of their analytical testing throughout the drug development lifecycle.